173 related articles for article (PubMed ID: 29967227)
1. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
Nassif ME; Kosiborod M
Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
[No Abstract] [Full Text] [Related]
2. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
Pagidipati NJ; Lopes RD
J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
[No Abstract] [Full Text] [Related]
3. Emerging glucose-lowering therapies: a guide for cardiologists.
Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
[TBL] [Abstract][Full Text] [Related]
4. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
Testani JM; Inzucchi SE; Voors AA
Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
[No Abstract] [Full Text] [Related]
5. New anti-diabetic agents: major advances with unanswered questions.
Sabouret P; Bocchino PP; Biondi-Zoccai G
Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
[TBL] [Abstract][Full Text] [Related]
6. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
7. Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.
Slater TA; Drozd M; Palin V; Bowles C; Waduud MA; Khatib R; Ajjan RA; Wheatcroft SB
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):194-196. PubMed ID: 31702003
[No Abstract] [Full Text] [Related]
8. The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.
Fatima S; Jameel A; Ayesha F; Menzies DJ
Clin Cardiol; 2017 Nov; 40(11):970-973. PubMed ID: 28841228
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
Shehadeh N; Raz I; Nakhleh A
Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
[No Abstract] [Full Text] [Related]
11. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Carbone S; Dixon DL
Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
[TBL] [Abstract][Full Text] [Related]
12. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
[TBL] [Abstract][Full Text] [Related]
13. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
Wagenaar P
Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
[No Abstract] [Full Text] [Related]
14. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
Xiang B; Zhao X; Zhou X
Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
[TBL] [Abstract][Full Text] [Related]
15. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Inzucchi SE; Kosiborod M; Fitchett D; Wanner C; Hehnke U; Kaspers S; George JT; Zinman B
Circulation; 2018 Oct; 138(17):1904-1907. PubMed ID: 30354665
[No Abstract] [Full Text] [Related]
16. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
Bertero E; Prates Roma L; Ameri P; Maack C
Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
[TBL] [Abstract][Full Text] [Related]
17. Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020.
Ferrannini G
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):341-342. PubMed ID: 32991694
[No Abstract] [Full Text] [Related]
18. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.
Tanaka A; Node K
Cardiovasc Diabetol; 2019 Feb; 18(1):19. PubMed ID: 30819188
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes.
Ghaffar ZA; Anwar S; Rizvi SW
J Coll Physicians Surg Pak; 2019 Feb; 29(2):195. PubMed ID: 30700368
[No Abstract] [Full Text] [Related]
20. New Therapeutic Strategies for Type 2 Diabetes
Yehya A; Sadhu AR
Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
